Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the completion of an investment by medac Gesellschaft fuer klinische Spezialpraeparate mbH. This investment, a continuation of Myconostica's series D round which had a first close in late 2009, will be used to further develop Myconostica's pipeline of products along with marketing the company's existing suite of diagnostic tests. Medac is an established and successful privately-held German pharmaceutical company with a growing pharmaceutical business and a diagnostics division, which acts as exclusive distributor of Myconostica's products in Germany. Dr Rainer Dickhardt, Managing Director of Medac's diagnostic business, joins Myconostica's board, and brings many years of experience in pharmaceuticals and diagnostics. Jerel Whittingham, Myconostica's Executive Chairman, said "I am delighted to complete this latest contribution to our ongoing fund raising programme. Medac, already a distribution partner, is a very successful business. This investment represents a strong endorsement of Myconostica's business plan as we develop our tests for invasive fungal infections. I am also delighted to welcome the additional insight and experience that Dr Rainer Dickhardt will bring to the Myconostica board and look forward to working with him." Kai Deusch, Managing Director of Medicis and Myconostica board member, said "Medac is a high quality, successful organization, which brings an additional richness to our already broad spectrum of investors as well as many perspectives on pipeline and strategic development." Rainer Dickhardt, Medac GmbH, said "Myconostica is making very good progress in the development of its diagnostic products and the overall strategy of providing healthcare professionals with a complete diagnostic toolkit for life threatening fungal infections." Financial terms were not disclosed. For further information please contact: Myconostica Ltd Spencer Kerry mycoinfo@myconostica.co.uk +44 (0)161 998 7239 Media Enquiries: Cardew Group Tim Robertson/ Matthew Law +44 020 7930 0777 medac GmbH www.medac.de +49 (0) 4103 8006 0 About Myconostica Ltd. Myconostica Ltd, a UK-based medical diagnostic company specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow. Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy. Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone. On the web: www.myconostica.co.uk About Medac: Medac GmbH is one of the leading companies, developing, manufacturing and marketing pharmaceuticals for the treatment of oncological and autoimmune diseases as well as diagnostics for the identification of cancer and infectious diseases. Medac strives for high quality and optimized therapies for cancer and rheumatic patients, also by using appropriate diagnostics to guarantee an optimal quality of life.